$26.1 0.1 0.5%
Last Trade - 14/05/21
| Market Cap | £506.8m |
| Enterprise Value | £236.9m |
| Revenue | £50.5m |
| Position in Universe | 3180th / 6846 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 17.6 | 16.7 | 10.00 | 5.00 | 8.00 | 75.0 | 64.0 | 70.4 | +33.7% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).
| Last Annual | December 31st, 2020 |
| Last Interim | March 31st, 2021 |
| Incorporated | November 16, 2005 |
| Public Since | January 26, 2017 |
| No. of Shareholders: | 13 |
| No. of Employees: | 94 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 27,369,199 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 10770 WATERIDGE CIRCLE SUITE 210, SAN DIEGO, 92121, United States |
| Web | https://www.anaptysbio.com/ |
| Phone | +1 858 3626295 |
| Contact | () |
| Auditors | KPMG LLP |
As of 14/05/21, shares in AnaptysBio Inc are trading at $26.1, giving the company a market capitalisation of £506.8m. This share price information is delayed by 15 minutes.
Shares in AnaptysBio Inc are currently trading at $26.1 and the price has moved by 44.44% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the AnaptysBio Inc price has moved by 0.58% over the past year.
Of the analysts with advisory recommendations for AnaptysBio Inc, there are there are currently 1 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for AnaptysBio Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
AnaptysBio Inc is scheduled to issue upcoming financial results on the following dates:
AnaptysBio Inc does not currently pay a dividend.
AnaptysBio Inc does not currently pay a dividend.
AnaptysBio Inc does not currently pay a dividend.
To buy shares in AnaptysBio Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in AnaptysBio Inc are currently trading at $26.1, giving the company a market capitalisation of £506.8m.
Here are the trading details for AnaptysBio Inc:
Based on an overall assessment of its quality, value and momentum, AnaptysBio Inc is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in AnaptysBio Inc are currently priced at $26.1. At that level they are trading at 24.52% discount to the analyst consensus target price of 0.00.
Analysts covering AnaptysBio Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.642 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AnaptysBio Inc. Over the past six months, the relative strength of its shares against the market has been -21.31%. At the current price of $26.1, shares in AnaptysBio Inc are trading at 14.85% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for AnaptysBio Inc.
AnaptysBio Inc's management team is headed by:
Here are the top five shareholders of AnaptysBio Inc based on the size of their shareholding:
